Business
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant ...
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Access the CEO Connect segment here","length":35,"tagName":"p"},{"type":"text","content":"HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment.","length":335,"tagName":"p"},{"type":"text","content":"As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company's broader growth outlook and investment thesis moving forward.","length":586,"tagName":"p"},{"type":"text","content":"The Virtual Investor CEO Connect segment is accessible here.","length":60,"tagName":"p"},{"type":"text","content":"About CNS Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.","length":473,"tagName":"p"},{"type":"text","content":"For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.","length":101,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncer...